Sotatercept for Pulmonary Arterial Hypertension
(LIGHTRAY EXT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a treatment called sotatercept for pulmonary arterial hypertension (PAH), which is high blood pressure in the lungs. Researchers aim to determine if weight-banded dosing (based on weight ranges) of sotatercept is safe and well-tolerated over an extended period. Participants who completed an earlier sotatercept study may join this trial, provided they have not started any other sotatercept treatment. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, you cannot start treatment with commercially available sotatercept or any activin signaling inhibitor other than sotatercept.
Is there any evidence suggesting that sotatercept is likely to be safe for humans?
Research has shown that sotatercept has been tested in people with pulmonary arterial hypertension (PAH) and has raised some safety concerns. In previous studies, more participants taking sotatercept experienced nosebleeds, dizziness, and small red spots on the skin compared to those taking a placebo. Some patients also had higher hemoglobin levels and fewer platelets.
However, sotatercept was associated with a lower risk of death and hospitalization for PAH patients, significantly improving survival rates. While some side effects exist, many patients have tolerated the treatment well. This suggests that sotatercept has a unique safety profile, and ongoing studies continue to assess its long-term safety and effectiveness.12345Why are researchers excited about this trial's treatment for pulmonary arterial hypertension?
Sotatercept is unique because it targets the underlying processes of pulmonary arterial hypertension (PAH) differently than current treatments. Most PAH therapies focus on dilating blood vessels, but sotatercept acts on the transforming growth factor-beta (TGF-β) superfamily, which is involved in cell growth and repair, potentially addressing the root cause of the disease. Additionally, sotatercept is administered via a convenient subcutaneous injection every three weeks, which could improve patient compliance compared to more frequent dosing schedules required by some existing therapies. Researchers are excited about sotatercept because it may offer a new way to manage PAH more effectively and with fewer side effects.
What evidence suggests that sotatercept might be an effective treatment for pulmonary arterial hypertension?
Research shows that sotatercept, which participants in this trial will receive, can help treat pulmonary arterial hypertension (PAH). Studies have found that sotatercept improves exercise capacity and reduces the risk of the condition worsening by 84%. It also lowers the chances of death, the need for a lung transplant, and long hospital stays compared to a placebo. Early results suggest that patients experience better heart function and few side effects, although hemoglobin levels may increase. These findings make sotatercept a promising treatment for PAH.56789
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for people who have Pulmonary Arterial Hypertension (PAH) and participated in a previous study, MK-7962-024 (LIGHTRAY), without discontinuing the intervention. They must not have started treatment with commercially available sotatercept to be eligible.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive weight-banded doses of sotatercept via subcutaneous injection every 3 weeks, continuing their background PAH therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants continue to receive weight-banded doses of sotatercept to evaluate long-term safety and tolerability
What Are the Treatments Tested in This Trial?
Interventions
- Sotatercept
Trial Overview
The trial is testing Sotatercept given in weight-banded doses as an extension of a prior study. It aims to evaluate the long-term safety and tolerability of this medication when used alongside standard PAH therapies.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will receive sotatercept via subcutaneous (SC) injection every 3 weeks at an initial dose of up to 45 mg and then at a maintenance dose of up to 90 mg using a weight-banded method and will continue treatment for up to 24 months. All eligible participants will receive weight-banded dosing at the dosing level (initial or maintenance) at which they finished MK-7962-024 (LIGHTRAY). Participants will continue to take their background PAH therapy during the study.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Citations
Sotatercept in Patients with Pulmonary Arterial ...
Background: Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) ...
Sotatercept Beneficial in Recent-Onset Pulmonary Arterial ...
The activin-signaling inhibitor improved clinical outcomes in patients when given within 1 year of PAH diagnosis. ... PAH based on trials in those ...
Early Outcomes of Sotatercept in Pulmonary Arterial ...
Mean RVFWS improved to -19% [-21% to -14.6%] (p = 0.032). Side effects were infrequent, except for an increment in Hb levels by a mean 1.92±1.4 g/dL (p<0.0001).
Sotatercept In High-Risk Patients With Pulmonary Arterial ...
Treatment with sotatercept resulted in a lower risk of all-cause death, lung transplantation, and hospitalization (≥24 hours) for worsening PAH than placebo.
The effectiveness and value of sotatercept for pulmonary ...
There was an 84% reduction in the risk of clinical worsening with sotatercept as assessed by a composite endpoint of time to first clinical ...
Phase 3 Trial of Sotatercept for Treatment of Pulmonary ...
Adverse events that occurred more frequently with sotatercept than with placebo included epistaxis, dizziness, telangiectasia, increased hemoglobin levels, ...
A New Frontier in Pulmonary Arterial Hypertension Treatment
Study selection and data extraction: Phase II and III trials assessing sotatercept's safety and efficacy were included. Initially, 796 trials ...
8.
ajmc.com
ajmc.com/view/sotatercept-for-pah-maintains-safety-reduced-mortality-in-long-term-follow-upSotatercept for PAH Maintains Safety, Reduced Mortality in ...
Sotatercept significantly reduced mortality risk by 85% in patients with PAH compared with placebo. · The safety profile of sotatercept remained ...
Sotatercept in pulmonary arterial hypertension
Sotatercept's safety profile is distinct. The main safety signals observed in clinical trials are increased haemoglobin, decreased platelet counts, ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.